The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Adoptive cellular therapy: A race to the finish line
Abstract
Engineered T cells are under development in academic-industry partnerships, accelerating the pace toward widespread availability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062 · cited 1×
“Zinc-f nger nucleases (ZFNs) and transcription activator–like ef ector nucleases (TALENS) that rely on customized DNA binding proteins, and the natural bacterial CRISPR-Cas9 system of RNA-guided nucleases, can introduce DNA double-strand breaks at specif c sites and lead to disruption of a gene sequence or provide a s…”
BackgroundOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationLong-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
Ho, Y.-C., Shan, L., Hosmane, N. N., Wang, J., Laskey, S. B., Rosenbloom, D. I. S., Lai, J., Blankson, J. N., Siliciano, J. D., & Siliciano, R. F. (2013) · Cell · doi:10.1016/j.cell.2013.09.020 · Cited by 1,405
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Self-citationA Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
A guide to genome engineering with programmable nucleases
Kim, H., & Kim, J.-S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3686 · Cited by 1,163
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Self-citationCameron, B. J., Gerry, A. B., Dukes, J., Harper, J. V., Kannan, V., Bianchi, F. C., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 684
Self-citationLinnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Self-citationDecade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Self-citationWang, X., Chang, W.-C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600
Self-citationRiddell, S. R., Elliott, M., Lewinsohn, D. A., Gilbert, M. J., Wilson, L., Manley, S. A., Lupton, S. D., Overell, R. W., Reynolds, T. C., Corey, L., et al. (1996) · Nature Medicine · doi:10.1038/nm0296-216 · Cited by 565
Self-citationDeconstructing the Peptide-MHC Specificity of T Cell Recognition
Birnbaum, M. E., Mendoza, J. L., Sethi, D. K., Dong, S., Glanville, J., Dobbins, J., Özkan, E., Davis, M. M., Wucherpfennig, K. W., & Garcia, K. C. (2014) · Cell · doi:10.1016/j.cell.2014.03.047 · Cited by 556
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Torikai, H., Reik, A., Liu, P.-Q., Zhou, Y., Zhang, L., Maiti, S., Huls, H., Miller, J. C., Kebriaei, P., Rabinovitch, B., et al. (2012) · Blood · doi:10.1182/blood-2012-01-405365 · Cited by 528
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Deng, K., Pertea, M., Rongvaux, A., Wang, L., Durand, C. M., Ghiaur, G., Lai, J., McHugh, H. L., Hao, H., Zhang, H., et al. (2015) · Nature · doi:10.1038/nature14053 · Cited by 504
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
Bendle, G. M., Linnemann, C., Hooijkaas, A. I., Bies, L., de Witte, M. A., Jorritsma, A., Kaiser, A. D. M., Pouw, N., Debets, R., Kieback, E., et al. (2010) · Nature Medicine · doi:10.1038/nm.2128 · Cited by 448
Self-citationEditing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D. E., Zhang, L., Kuball, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2700 · Cited by 448
Billingham, R. E., Brent, L., & Medawar, P. B. (1954) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1954.0054 · Cited by 427
Disparate Individual Fates Compose Robust CD8 + T Cell Immunity
Buchholz, V. R., Flossdorf, M., Hensel, I., Kretschmer, L., Weissbrich, B., Gräf, P., Verschoor, A., Schiemann, M., Höfer, T., & Busch, D. H. (2013) · Science · doi:10.1126/science.1235454 · Cited by 412
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., et al. (2014) · Blood · doi:10.1182/blood-2014-01-545020 · Cited by 397
Lamers, C. H. J., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., & Gratama, J. W. (2011) · Blood · doi:10.1182/blood-2010-07-294520 · Cited by 368
Heterogeneous Differentiation Patterns of Individual CD8 + T Cells
Gerlach, C., Rohr, J. C., Perié, L., van Rooij, N., van Heijst, J. W. J., Velds, A., Urbanus, J., Naik, S. H., Jacobs, H., Beltman, J. B., et al. (2013) · Science · doi:10.1126/science.1235487 · Cited by 365
Self-citationNaïve and Memory CD4 + T Cell Survival Controlled by Clonal Abundance
Hataye, J., Moon, J. J., Khoruts, A., Reilly, C., & Jenkins, M. K. (2006) · Science · doi:10.1126/science.1124228 · Cited by 351
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Berger, C., Flowers, M. E., Warren, E. H., & Riddell, S. R. (2006) · Blood · doi:10.1182/blood-2005-08-3503 · Cited by 334
Self-citationToward eliminating HLA class I expression to generate universal cells from allogeneic donors
Torikai, H., Reik, A., Soldner, F., Warren, E. H., Yuen, C., Zhou, Y., Crossland, D. L., Huls, H., Littman, N., Zhang, Z., et al. (2013) · Blood · doi:10.1182/blood-2013-03-478255 · Cited by 311
Leukemia Following Chemotherapy for Ovarian Cancer
Kaldor, J. M., Day, N. E., Pettersson, F., Clarke, E. A., Pedersen, D., Mehnert, W., Bell, J., Høst, H., Prior, P., Karjalainen, S., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220101 · Cited by 279
In vivo discovery of immunotherapy targets in the tumour microenvironment
Zhou, P., Shaffer, D. R., Alvarez Arias, D. A., Nakazaki, Y., Pos, W., Torres, A. J., Cremasco, V., Dougan, S. K., Cowley, G. S., Elpek, K., et al. (2014) · Nature · doi:10.1038/nature12988 · Cited by 237
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Koya, R. C., Mok, S., Otte, N., Blacketor, K. J., Comin-Anduix, B., Tumeh, P. C., Minasyan, A., Graham, N. A., Graeber, T. G., Chodon, T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2837 · Cited by 234
Rossi, J. J., June, C. H., & Kohn, D. B. (2007) · Nature Biotechnology · doi:10.1038/nbt1367 · Cited by 231
Self-citationLineage relationship of effector and memory T cells
Restifo, N. P., & Gattinoni, L. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.09.003 · Cited by 228
Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells
Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 173
Self-citationSattler, S., Ling, G.-S., Xu, D., Hussaarts, L., Romaine, A., Zhao, H., Fossati-Jimack, L., Malik, T., Cook, H. T., Botto, M., et al. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.032 · Cited by 173
Lesokhin, A. M., Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010274 · Cited by 169
Berdien, B., Mock, U., Atanackovic, D., & Fehse, B. (2014) · Gene Therapy · doi:10.1038/gt.2014.26 · Cited by 160
Mirsoian, A., Bouchlaka, M. N., Sckisel, G. D., Chen, M., Pai, C.-C. S., Maverakis, E., Spencer, R. G. S., Fishbein, K. W., Siddiqui, S., Monjazeb, A. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20140116 · Cited by 146
Davis, J. L., Theoret, M. R., Zheng, Z., Lamers, C. H. J., Rosenberg, S. A., & Morgan, R. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1280 · Cited by 132
Transgenic mice with a diverse human T cell antigen receptor repertoire
Li, L.-P., Lampert, J. C., Chen, X. T., Leitão, C., Popović, J., Müller, W., & Blankenstein, T. J. F. (2010) · Nature Medicine · doi:10.1038/nm.2197 · Cited by 123
Drujont, L., Carretero-Iglesia, L., Bouchet‐Delbos, L., Bériou, G., Mérieau, E., Hill, M., Delneste, Y., Cuturi, M. C., & Louvet, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100013 · Cited by 69
T-Cell Immunotherapy: Looking Forward
Corrigan‐Curay, J., Kiem, H., Baltimore, D., O’Reilly, M., Brentjens, R. J., Cooper, L. J. N., Forman, S. J., Gottschalk, S. M., Greenberg, P. D., Junghans, R. P., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.148 · Cited by 65
Self-citationBlockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer
Bendle, G. M., Linnemann, C., Bies, L., Song, J., & Schumacher, T. N. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301270 · Cited by 45
Self-citationBlockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Peng, W., Lizee, G. A., & Hwu, P. (2013) · OncoImmunology · doi:10.4161/onci.22691 · Cited by 36
Cited by
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Self-citationChimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Self-citationGene therapy returns to centre stage
Naldini, L. (2015) · Nature · doi:10.1038/nature15818 · Cited by 1,184
Current Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Metadata
- Authors
- June, C. H., Riddell, S. R., & Schumacher, T. N.
- Venue
- Science Translational Medicine
- Published
- 2015-03-25
- Volume
- 7
- Issue
- 280
- Pages
- 280ps7-280ps7
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2130830673
- Cited by
- 403
- References
- 55
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.